Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $68.02 USD
Change Today -0.12 / -0.18%
Volume 3.3M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 8:04 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Key Developments

Baxter International Inc. Amends and Restates its Bylaws

On March 24, 2015, the Bylaws of Baxter International Inc. were amended and restated to remove the mandatory director retirement age from Section 2 Article II. The foregoing description of the amendment and restatement of the Bylaws is qualified in its entirety by reference to the text of the Bylaws, as amended and restated on March 24, 2015.

Baxter Bioscience Announces Positive Phase III Results for BAX 817

Baxter International Inc. announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors. The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 µg/kg or 1x270 µg/kg, with an overall success rate of 92% (98% and 85% in each dosing group, respectively). Further, 89% of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion.

Baxter International Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM

Baxter International Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

CTI BioPharma Corp. and Baxter International Inc. Announce Positive Top-Line Results from Phase 3 Persist-1 Trial of Pacritinib for Patients with Myelofibrosis

CTI BioPharma Corp. and Baxter International Inc. announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. The PERSIST-1 trial met its primary endpoint in the intent-to-treat population with statistically significant activity observed in patients irrespective of their initial platelet count, including patients with very low platelet counts at study entry, a condition known as severe or life-threatening thrombocytopenia. The primary endpoint of the trial was the proportion of patients achieving a 35% or greater reduction in spleen volume from baseline to Week 24 as measured by magnetic resonance imaging (MRI) or computerized tomography (CT) when compared with physician-specified best available therapy (BAT), excluding treatment with JAK2 inhibitors. The PERSIST-1 trial demonstrated that pacritinib treatment provided a clinically and statistically significant response rate (p = 0.0003) in spleen volume reduction in patients with myelofibrosis when compared to BAT. Importantly, the trial results also demonstrated a significant difference among patients with platelet counts of less than 100,000 per microliter and less than 50,000 per microliter, both subgroups that were stratified at randomization. The magnitude of treatment effect was consistent with previously reported Phase 2 results, with the great reduction observed among the sickest patients (platelet counts <50,000 per microliter). Among 50 patients who were red blood cell (RBC) transfusion dependent at study entry (= 6 units of RBC over 90 days pre entry), pacritinib therapy resulted in a clinically meaningful percentage of patients becoming transfusion independent compared to BAT. 79% of patients in the BAT arm of the study crossed over to pacritinib therapy. The safety profile in the PERSIST-1 trial was consistent with prior Phase 2 trials. While the most common treatment emergent adverse events were diarrhea, nausea and vomiting, the incidence of grade 3 events was lower than observed in Phase 2 trials. No grade 4 gastrointestinal adverse events were reported. Three patients discontinued therapy and nine patients required dose reduction for diarrhea. Preliminary analysis suggests that very few patients discontinued treatment while on pacritinib or required a dose reduction due to treatment-related anemia or thrombocytopenia. Additional data from ongoing analyses along with top-line results from PERSIST-1 will be submitted for presentation at an upcoming scientific meeting. Pacritinib is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis. The PERSIST clinical trials are intended to support a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Baxter International Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 through Mar-12-2015

Baxter International Inc. Presents at Barclays Global Healthcare Conference, Mar-10-2015 through Mar-12-2015. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Presentation Date & Speakers: Mar-10-2015, Robert J. Hombach, Chief Financial Officer and Corporate Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $68.02 USD -0.12

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,950 JPY -27.50
CSL Ltd A$91.85 AUD +0.15
Kimberly-Clark Corp $106.32 USD -1.14
Stryker Corp $91.53 USD -0.76
Takeda Pharmaceutical Co Ltd ¥6,111 JPY -134.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 19.2x
Price/Sales 2.2x
Price/Book 4.6x
Price/Cash Flow 14.8x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.